

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (Review of TA762)

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|--|
| <p>1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?</p> |
|--|

<p>No equalities issues were identified in the original appraisal.</p>
--

<p>Issues identified by the MOT report outlining suitability for cost comparison included:</p>
--

<p>1. HER2-negative breast cancer with germline BRCA mutations may be more common in some population groups, such as younger people and people of Black ethnicity.</p>
--

<p>2. BRCA mutations are more common in people of Ashkenazi Jewish ethnicity.</p>

<p>3. Although breast cancer is rare in men, it is more common in men with BRCA mutations than other men.</p>

- | |
|--|
| <p>2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?</p> |
|--|

<p>NICE considers appraisal technologies within their marketing authorisation for the whole population. Stakeholders will have an opportunity to submit evidence on health inequalities. As part of the technology appraisal and the committee will consider the impact of recommendations on people with protected characteristics in conjunction with the principles that guide the</p>

Technology Appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal for olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (Review of TA762)

Issue date: April 2024

development of NICE guidance and standards including the aim to reduce health inequalities. However, please note:

1. Issues related to differences in prevalence or incidence of a disease or a reduced life expectancy for one particular protected group cannot be addressed in a technology appraisal.

2. The committee must follow the processes and methods set out in the NICE health technology evaluation manual and are unable to divert from these methods and processes for individual evaluations or they will risk introducing further inequalities.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): ...Emily Crowe...

Date: ...01/05/2024.